drugset / Trial / NCT01969435

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

NCT01969435

Phase 2 Completed 50 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT

Timeline

Start
2014-03-19
Primary completion
2015-09-30
Completion
2017-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule Intravenous
Background Cytarabine Small molecule Intravenous
Background Etoposide Small molecule Intravenous
Background carmustine Small molecule Intravenous